The findings deliver early evidence that semaglutide may offer a dual benefit, targeting obesity and key reproductive challenges associated with the condition, including irregular menstruation and impaired fertility. Clare Thompson, MBBS, BSc, nMRCGP Separately, a review of five randomized controlled trials presented at ENDO 2026 found that GLP-1 drugs, such as semaglutide and liraglutide, do not appear to harm male fertility and may even improve testosterone levels and sperm quality in some men with obesity
This information proves valuable when discussing your progress with healthcare providers
The harder challenge for patients, doctors, and health systems is keeping it off and sustaining the broader health gains that come with it
A systematic evaluation of effect of adherence patterns on the sample size and power of a clinical study
Dark yellow or amber urine means you are already significantly behind on hydration
CVD, the predominant cause of mortality in T2D, requires therapeutic strategies extending beyond glucose control